AbCellera reports FY25 EPS (49c) vs. (55c) last year

Reports FY25 revenue $75.1M vs. $28.8M last year. “In 2025, AbCellera (ABCL) successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of pipeline investments.”